Bibliographic record
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised…
Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT. The Lancet 2023
§1Bibliographic record
§1.1Record
- Authors
- Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT
- Title
- Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
- Source
- The Lancet
- Year
- 2023
- Volume, issue, pages
- 402(10403):705–719
- Digital object identifier
- 10.1016/S0140-6736(23)01185-6
- PubMed identifier
- 37364590
- Record type
- Journal article
- Institute identifier
- CEI-BR-059
§1.2Institute documents citing this record
Table 1. Documents in the Institute set that cite this record.
| Document | Series |
|---|---|
| Monograph: Semaglutide, oral | Compound monograph |
| Synthesis: Semaglutide, oral in type 2 diabetes mellitus: effect on the anchor… | Evidence synthesis |
| Synthesis: Semaglutide, oral in atherosclerotic cardiovascular disease and… | Evidence synthesis |
| Synthesis: Semaglutide, oral in type 2 diabetes mellitus: tolerability and… | Evidence synthesis |
| Synthesis: Semaglutide, oral in atherosclerotic cardiovascular disease and… | Evidence synthesis |
| Synthesis: Semaglutide, oral in type 2 diabetes mellitus: durability of effect | Evidence synthesis |
| 6 citing documents. | |
§1.3Subject tags
oral-semaglutide obesity OASIS
Compound Evidence Institute · CEI-BR-059 · https://compoundevidence.com/bibliography/knop2023/ · retrieved 30 July 2026